IL2 and cancer: This has led to the development of a variety of cancer immunotherapeutic agents, such as recombinant stimulatory cytokines (e.g., IL-2, IFN-α), immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1), and CAR-T cell therapy (Cortés-Selva et al., 2021; Kraehenbuehl et al., 2022; Propper and Balkwill, 2022).